MetrioPharm AG Investor Relations News
-
Investor Relations News QIII 2023
Financing Round Continues, Development in Duchenne Muscular Dystrophy (DMD), MetrioPharm Company Calendar H2, MetrioPharm informs
-
Investor Relations News QII 2023
MetrioPharm AG has started a new financing round, 17th Annual General Meeting of MetrioPharm AG, Company Calendar, MetrioPharm informs
-
Investor Relations News QI 2023
Invitation to a Webinar, Company Calendar, MetrioPharm informs
-
Investor Relations News QIV 2022
Holiday Greetings from CEO Thomas Christély
-
Investor Relations News QIII 2022
MetrioPharm at BioPharm America in Boston, USA, Company Calendar in QIV 2022, MetrioPharm blog, MetrioPharm at Linkedin
-
Investor Relations News QII 2022
16th Annual General Meeting of MetrioPharm AG, Bio-Europe Spring in Basel, BIO International Convention in San Diego, Company Calendar, London-Paris in 24 hours, MetrioPharm AG informs
-
Investor Relations News QI 2022
Outlook by the Chairman of the Board Rudolf Stäger
-
Investor Relations News QIV 2021
Greetings from CEO Thomas Christély
-
Investor Relations News QIII 2021
Topics: Greetings from CEO Thomas Christély, MetrioPharm in the Media
-
Investor Relations News QII 2021
Topics: 15th Annual General Meeting of MetrioPharm AG, MetrioPharm in the Media